In this study, we provide evidence that: i) CMIP is selectively expressed in the cytoplasm compartment of podocytes in class II and class V glomerulopathies, suggesting that podocyte is presumably the main target in these lupus glomerulopathies; ii) in proliferative forms (class III/IV), CMIP is almost not expressed either in podocytes or in cellular crescents; iii) there is no correlation between classical immunological markers and CMIP expression; iv) expression of CMIP in podocytes is associated with a better response to therapy. Here, CMIP is linked to glomerular disorder.